Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Seletracetam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA3 | P07451 | 1/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA6 | P23280 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Seletracetam SCHEMBL2791729 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL563418 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL432316 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL1171958 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL10297428 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL563196 | 1.00 | LMNA (0.47) | LMNACA12CA1CA2CA3 | |
| SCHEMBL662105 | 0.92 | LMNA (0.51) | LMNACA12CA1CA2CA3 | |
| Seletracetam SCHEMBL28185618 | 0.91 | LMNA (0.43) | LMNACA12CA1CA2CA3 | |
| SCHEMBL662315 | 0.90 | LMNA (0.52) | LMNACA12CA1CA2CA3 | |
| SCHEMBL23561339 | 0.89 | MAPT (0.36) | LMNACA12CA1CA2CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1464 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2025-09-18 | — | — | US | claimed |
| US-20250228820-A1 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS DISPLAYING NORMAL COGNITIVE PERFORMANCE | NATIONAL INSTITUTES OF HEALTH | 2025-07-17 | — | — | US | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| CN-119730849-A | Methods for preventing or slowing progression of cognitive decline or impairment in subjects exhibiting normal cognitive performance | 艾吉因生物股份有限公司 | 2025-03-28 | — | — | CN | claimed |
| WO-2024151951-A1 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | AGENEBIO, INC. (US) | 2024-07-18 | — | — | WO | claimed |
| US-20240238246-A1 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS | AGENEBIO INC (US) | 2024-07-18 | — | — | US | claimed |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2024-04-25 | — | — | US | claimed |
| WO-2024039886-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| CN-115448865-B | Asymmetric synthesis method of cetracetam intermediate | 武汉大学 | 2023-11-17 | — | — | CN | claimed |
| WO-2023192686-A1 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS DISPLAYING NORMAL COGNITIVE PERFORMANCE | Li shi jiang (US) | 2023-10-05 | — | — | WO | claimed |
| US-20040242671-A1 | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | UCB, S.A. (BE) | 2004-12-02 | — | — | US | claimed |
| US-6806287-B2 | NEUROLOGICAL DISORDERS; SUCH AS 2-(4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL)BUTANAMIDE | UCB, S.A. (BE) | 2004-10-19 | — | — | US | claimed |
| US-6784197-B2 | SUCH AS (2S)-2-((4S)-4-(2,2-DIFLUOROVINYL)-2-OXOPYRROLIDINYL) BUTANAMIDE; ANTIEPILEPTIC AGENTS; ANTICONVULSANTS | UCB S.A. (BE) | 2004-08-31 | — | — | US | claimed |
| EP-1447399-A1 | \"2-oxo-1-pyrrolidine derivative and its pharmaceutical uses\ | UCB, S.A. (BE) | 2004-08-18 | — | — | EP | claimed |
| EP-1435943-A2 | USE OF 2-OXO-1-PYRROLIDINE DERIVATIVES FOR THE PREPARATION OF A DRUG FOR TREATING DYSKINESIA | UCB, S.A. (BE) | 2004-07-14 | — | — | EP | claimed |
| US-20040087646-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB BIOPHARMA SPRL (BE) | 2004-05-06 | — | — | US | claimed |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB Biopharma SRL (BE) | 2003-06-26 | — | — | US | claimed |
| WO-2003030899-A2 | USE OF 2-OXO-1-PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF DYSKINESIA AND MOVEMENT DISORDERS | UCB, S.A. (BE) | 2003-04-17 | — | — | WO | claimed |
| EP-1265862-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2002-12-18 | — | — | EP | claimed |
| WO-2001062726-A2 | 2-OXO-1-PYRROLIDINE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES | UCB, S.A. (BE) | 2001-08-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288584-A1 | COMBINATIONS COMPRISING POSITIVE ALLOSTERIC MODULATORS OR ORTHOSTERIC AGONISTS OF METABOTROPIC GLUTAMATERGIC RECEPTOR SUBTYPE 2 AND THEIR USE | GRM2, GRIN2A, GRIK2 | LMNA 4659/4885CA12 2694/4885CA1 2262/4885 |
| US-20030120080-A1 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, CYP1A2, OGDH | LMNA 3771/4885CA12 4126/4885CA1 1842/4885 |
| US-20040087646-A1 | 2-Oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | CYP1B1, CYP1A2, OGDH | LMNA 3802/4885CA12 4185/4885CA1 1667/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | LMNA 4093/4885CA12 4047/4885CA1 2801/4885 |
| US-20040242671-A1 | Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug | PARK7, OPA1, OTC | LMNA 3519/4885CA12 4444/4885CA1 1982/4885 |
| US-20240132513-A1 | BENZAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRB1 | LMNA 1853/4885CA12 3694/4885CA1 1854/4885 |
| US-20250228820-A1 | METHODS FOR PREVENTING OR SLOWING THE PROGRESSION OF COGNITIVE DECLINE OR IMPAIRMENT IN SUBJECTS DISPLAYING NORMAL COGNITIVE PERFORMANCE | GABRA5, SLC6A1, GABRA1 | LMNA 1988/4885CA12 2886/4885CA1 817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.